Background Psoriatic arthritis (PsA) is a clinically heterogeneous disease. Clear consensual treatment guidance focused on the musculoskeletal manifestations of PsA would be advantageous. The authors present European League Against Rheumatism (EULAR) recommendations for the treatment of PsA with systemic or local (non-topical) symptomatic and disease-modifying antirheumatic drugs (DMARD). Methods The recommendations are based on evidence from systematic literature reviews performed for non-steroidal anti-inflammatory drugs (NSAID), glucocorticoids, synthetic DMARD and biological DMARD. This evidence was discussed, summarised and recommendations were formulated by a task force comprising 35 representatives, and providing levels of evidence, strength of recommendations and levels of agreement. Results Ten recommendations were developed for treatment from NSAID through synthetic DMARD to biological agents, accounting for articular and extra-articular manifestations of PsA. Five overarching principles and a research agenda were defined. Conclusion These recommendations are intended to provide rheumatologists, patients and other stakeholders with a consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes, based on combining evidence and expert opinion. The research agenda informs directions within EULAR and other communities interested in PsA.

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies / L., Gossec; J. S., Smolen; C., Gaujoux Viala; Z., Ash; H., Marzo Ortega; D., Van Der Heijde; O., Fitzgerald; D., Aletaha; P., Balint; D., Boumpas; J., Braun; F. C., Breedveld; G., Burmester; J. D., Canete; M., De Wit; H., Dagfinrud; K., De Vlam; M., Dougados; P., Helliwell; A., Kavanaugh; T. K., Kvien; R., Landewe; T., Luger; M., Maccarone; D., Mcgonagle; N., Mchugh; I. B., Mcinnes; C., Ritchlin; J., Sieper; P. P., Tak; Valesini, Guido; J., Vencovsky; K. L., Winthrop; A., Zink; P., Emery. - In: ANNALS OF THE RHEUMATIC DISEASES. - ISSN 0003-4967. - STAMPA. - 71:1(2012), pp. 4-12. [10.1136/annrheumdis-2011-200350]

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

VALESINI, Guido;
2012

Abstract

Background Psoriatic arthritis (PsA) is a clinically heterogeneous disease. Clear consensual treatment guidance focused on the musculoskeletal manifestations of PsA would be advantageous. The authors present European League Against Rheumatism (EULAR) recommendations for the treatment of PsA with systemic or local (non-topical) symptomatic and disease-modifying antirheumatic drugs (DMARD). Methods The recommendations are based on evidence from systematic literature reviews performed for non-steroidal anti-inflammatory drugs (NSAID), glucocorticoids, synthetic DMARD and biological DMARD. This evidence was discussed, summarised and recommendations were formulated by a task force comprising 35 representatives, and providing levels of evidence, strength of recommendations and levels of agreement. Results Ten recommendations were developed for treatment from NSAID through synthetic DMARD to biological agents, accounting for articular and extra-articular manifestations of PsA. Five overarching principles and a research agenda were defined. Conclusion These recommendations are intended to provide rheumatologists, patients and other stakeholders with a consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes, based on combining evidence and expert opinion. The research agenda informs directions within EULAR and other communities interested in PsA.
2012
01 Pubblicazione su rivista::01a Articolo in rivista
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies / L., Gossec; J. S., Smolen; C., Gaujoux Viala; Z., Ash; H., Marzo Ortega; D., Van Der Heijde; O., Fitzgerald; D., Aletaha; P., Balint; D., Boumpas; J., Braun; F. C., Breedveld; G., Burmester; J. D., Canete; M., De Wit; H., Dagfinrud; K., De Vlam; M., Dougados; P., Helliwell; A., Kavanaugh; T. K., Kvien; R., Landewe; T., Luger; M., Maccarone; D., Mcgonagle; N., Mchugh; I. B., Mcinnes; C., Ritchlin; J., Sieper; P. P., Tak; Valesini, Guido; J., Vencovsky; K. L., Winthrop; A., Zink; P., Emery. - In: ANNALS OF THE RHEUMATIC DISEASES. - ISSN 0003-4967. - STAMPA. - 71:1(2012), pp. 4-12. [10.1136/annrheumdis-2011-200350]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/420334
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 86
  • Scopus 379
  • ???jsp.display-item.citation.isi??? 354
social impact